Dynavax Technologies Corp (NAS:DVAX)
$ 13 -0.03 (-0.23%) Market Cap: 1.71 Bil Enterprise Value: 1.17 Bil PE Ratio: 100.23 PB Ratio: 2.51 GF Score: 70/100

Q2 2020 Dynavax Technologies Corp Earnings Call Transcript

Aug 06, 2020 / 08:30PM GMT
Release Date Price: $8.82 (-1.89%)
Operator

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Second Quarter 2020 Conference Call. As a reminder, this conference call is being recorded. (Operator Instructions) I would now like to turn the conference over to Nicole Arndt, Senior Manager, Investor Relations. You may begin.

Nicole Arndt
Dynavax Technologies Corporation - Senior Manager of IR

Thank you, operator. Good afternoon. Welcome to the Dynavax Second Quarter 2020 Financial Results and Corporate Update Conference Call. Joining me on the call today are Ryan Spencer, Chief Executive Officer; Michael Ostrach, Chief Financial Officer; Robert Janssen, Chief Medical Officer and Senior Vice President, Clinical Development; and Donn Casale, Vice President, Commercial.

Before we begin, I advise you that we will be making forward-looking statements today, including statements regarding HEPLISAV-B's commercial profile, revenue expectations, potential peak revenue, the completion of post-marketing study and regarding vaccine development potential with CpG 1018. These statements are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot